Tormere Analytics
OverviewStock ResearchPortfolio LabOptions LabCalculatorsWatchlist
Data Explorer
Pricing
Privacy PolicyTerms of Service

FEMY

$2.74+2.24%

FEMASYS INC

Market Cap
$23M
Sector
Health Care
Industry
Health Care
Beta
-2.24
5yr monthly vs SPY
Price Chart
Loading…

Signals

Insider Velocity
25.6x
buying
Congress
—
recent trades
Short Volume
18%
W/W -23.7pp

Market & Alt Data

News
8
recent articles
Activist
13D
FEMASYS
Analyst Consensus
Strong Buy
9 analysts
Velocity Score
25.65x
Current Rate (90d)
256.94/mo
Baseline Rate
0.00/mo
Unique Buyers (90d)
3
Sort by
Type
Trade DateFiledOwnerRoleTypeSharesPriceValueOwned After
2026-08-072026-08-11Canning John CharlesChief Operating OfficerPurchase4,375$3.20$14K4,375View
2026-08-072026-08-11Elefant DovChief Financial OfficerPurchase15.6K$3.20$50K15.6KView
2026-08-072026-08-11Sipos Jeremy AlexanderChief Technology OfficerPurchase3,125$3.20$10K3,125View

Recent News

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations
Yahoo Finance · 2026-08-26
Femasys Secures FDA Pathway for Non-Surgical Contraceptive
Yahoo Finance · 2026-08-19
FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential
Yahoo Finance · 2026-08-19
Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc

Informational purposes only, not investment advice.

Yahoo Finance · 2026-08-19
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®
Yahoo Finance · 2026-08-19
Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents
Yahoo Finance · 2026-08-12
Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million
Yahoo Finance · 2026-08-07
Femasys Regains Compliance with Nasdaq Listing Requirements
Yahoo Finance · 2026-06-24

Factor Profile

Pro
Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro →
Pipeline
Active
2 active trials